News Headlines

  1. TECPR2 Research Foundation And Forge Biologics Announce AAV Development And Manufacturing Partnership To Advance Gene Therapy For TECPR2 9/29/2026

    The TECPR2 Research Foundation, a nonprofit organization established to advance research and development of a treatment for patients with TECPR2, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to advance an AAV gene therapy for patients with TECPR2, an ultra-rare neurodegenerative genetic disease.

  2. Chugai And InxMed Enter Into A Worldwide License Agreement For SPYK04, A RAF-MEK Molecular Glue 9/29/2026

    Chugai Pharmaceutical Co., Ltd. and InxMed (Hong Kong) Limited (hereafter “InxMed”) today announced that they have entered into a worldwide license agreement regarding SPYK04, a RAF-MEK molecular glue discovered by Chugai for the treatment of solid tumors.

  3. Novo And Hengrui Pharma Enter Exclusive License Agreement For Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596 9/29/2026

    Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.

  4. Merck Enters Into Exclusive Global License Agreement With SciBrunch Therapeutics For SPR2015, An Investigational Oral KRAS G12D (ON) Inhibitor 9/28/2026

    Merck, known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.

  5. AstraZeneca Announces Strategic Equity Investment And Clinical Collaboration With Summit Therapeutics To Advance Leading ADC Combination Strategy In Cancer 9/28/2026

    AstraZeneca has entered into an agreement to invest $2B in newly issued equity in Summit Therapeutics Inc. to accelerate the development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody drug conjugates (ADCs) across tumour types.

  6. MindRank Partners With 3SBio To Commercialize Its AI-Designed Oral GLP-1 In China 9/28/2026

    MindRank AI Ltd. ("MindRank") today announced that it has entered into a strategic commercialization agreement with Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. ("Mandi") and Zhejiang Wansheng Pharmaceutical Co., Ltd. ("Wansheng"), both subsidiaries of 3SBio Inc. (01530.HK) group, for MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist in a pivotal Phase 3 trial in China for obesity and overweight.

  7. Rottendorf Pharma Is CDMO Leadership Award Winner 2025 9/28/2026

    Thanks to overwhelmingly positive customer feedback, Rottendorf Pharma has been awarded the CDMO Leadership Award 2025 in the category of "Small Molecule Dosage Form - International."

  8. Top Employer 2025: Rottendorf Pharma Receives International Award 9/28/2026

    Rottendorf Pharma has been recognized as a Top Employer 2025 in Germany. The Top Employer Institute, headquartered in Amsterdam, has assessed and certified more than 2,400 companies in 125 countries. 

  9. New Gerteis Roller Compactors: Rottendorf Pharma Invests Millions In State-Of-The-Art Technology 9/28/2026

    Rottendorf Pharma has commissioned a new dry granulation system from Swiss manufacturer Gerteis Maschinen + Processengineering AG at its Ennigerloh site.

  10. Rottendorf Pharma To Double Long-Term Manufacturing Capacity With New Campus 9/28/2026

    Rottendorf Pharma has officially begun construction of the Rottendorf Campus in Oelde, Germany, a major investment aimed at expanding manufacturing capacity for the global pharmaceutical industry.